Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors
作者:Yue-Yang Ji、Sen-Dong Lin、Yu-Jie Wang、Ming-Bo Su、Wei Zhang、Hendra Gunosewoyo、Fan Yang、Jia Li、Jie Tang、Yu-Bo Zhou、Li-Fang Yu
DOI:10.1016/j.ejmech.2017.09.073
日期:2017.12
been identified as potent LSD1 inhibitors, with a handful of them currently being tested in clinical trials. However, thus far the majority of structure-activity relationship studies reported on these TCP derivatives have been mostly limited to the racemates. In this study, we present the SAR data for a novel series of conformationally-restricted TCP-based LSD1 inhibitors, both in their racemic and enantiomerically
赖氨酸特异性组蛋白脱甲基酶1(LSD1)的异常表达已与众多癌细胞越来越相关,并且一些概念验证研究强烈暗示了其作为可治疗靶标的潜力。tranylcypromine(TCP)是一种抗抑郁药,最初已知其靶向单胺氧化酶A和B(MAO-A和MAO-B),它们与LSD1在结构上相关。许多TCP衍生物已被确认为有效的LSD1抑制剂,其中一些目前正在临床试验中进行测试。但是,到目前为止,有关这些TCP衍生物的大多数构效关系研究都主要限于外消旋体。在这项研究中,我们提出了一系列新的构象受限的基于TCP的LSD1抑制剂的SAR数据,这些形式均为外消旋和对映体纯形式。18b和19b被确定为该系列中最有效的LSD1抑制剂,对MAO-A和MAO-B具有极好的选择性(> 10,000倍)。暴露10天后,这些化合物激活了人MV4-11 AML细胞上的CD86表达,并伴有明显的细胞毒性。综上所述,这些发现与LSD1的药理